國家衛生研究院 NHRI:Item 3990099045/14068

NHRI > Institute of Molecular and Genomic Medicine > Shiu-Feng Kathy Huang > Periodical Articles > Item 3990099045/14068

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14068

Title:	The expression and prognostic value of cancer stem cell markers, NRF2, and its target genes in TAE/TACE-treated hepatocellular carcinoma
Authors:	Tseeleesuren, D;Hsiao, HH;Kant, R;Huang, YC;Tu, HP;Lai, CC;Huang, SF;Yen, CH
Contributors:	Institute of Molecular and Genomic Medicine
Abstract:	Background and Objectives: Activation of NRF2, a key transcription factor of cytoprotectant against oxidative stress, and its target genes are associated with aggressive tumor progression, metastasis and poor survival. In addition, NRF2 signaling mediates cancer stem cell (CSC)-like properties in hepatocellular carcinoma (HCC) cells. Moreover, CSCs have been associated with HCC onset and unfavorable prognosis. Transcatheter arterial embolization (TAE) and/or transcatheter arterial chemoembolization (TACE), which attempt to restrict blood supply to diminish tumor growth, can create a hypoxic environment. However, its effect on NRF2 signaling and CSC marker CD133 in the context of prognosis of HCCs have not been investigated. Therefore, we studied the possible role of the expressions of NRF2, its target genes and CSC markers CD133 and EpCAM on the survival of HCC patients after TAE/TACE. Materials and Methods: RT-qPCR was performed with 120 tumor (T) and adjacent tumor (N) tissue pairs. Expression of a single marker or combination was assessed for associations with survival of HCC patients after TAE/TACE. Results: The result of multivariate Cox regression showed that vascular invasion (HR, 1.821; p = 0.015), metastasis (HR, 2.033; p = 0.049) and CD133 overexpression (HR, 2.013; p = 0.006) were associated with poor survival. In a Kaplan–Meier survival analysis, patients with high expression of CD133 had shorter overall survival (OS) than those with low expression of CD133 in post-TAE/TACE HCC (p < 0.001). In contrast, neither NRF2 nor components of its signaling pathway correlated with survival. Combination marker analysis showed that co-expression of NQO1 and CD133 was associated with poor outcome. Conclusions: This study suggests that analyzing the expression status of CD133 alone and co-expression of NQO1 and CD133 may have additional value in predicting the outcome of TAE/TACE-treated HCC patients.
Date:	2022-02-01
Relation:	Medicina. 2022 Feb 01;58(2):Article number 212.
Link to:	http://dx.doi.org/10.3390/medicina58020212
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1010-660X&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000769121400001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85124166645
Appears in Collections:	[Shiu-Feng Kathy Huang] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85124166645.pdf		482Kb	Adobe PDF	187	View/Open

Loading...